Skip to main content

Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial

The Original Article was published on 16 February 2021

Correction to: Diabetes Ther (2021) 12:863–877 https://doi.org/10.1007/s13300-021-01014-0

The original article has been published with some errors.

The correct Table 2, Fig. 2, and Fig. 3 are given below.

Table 2 Clinical outcomes

In the results section of Abstract, there is correction in the sentence, the correct sentence is ‘‘HOMA-IR significantly decreased but HOMA-β was unchanged. FLI, ferritin, M2-BP, NAFLD fibrosis scores, and FIB-4 index significantly decreased whereas type IV collagen 7S domain did not significantly change’’.

In the Hepatic Function Biomarkers section of Results, the corrections in a sentence is ‘‘The NAFLD fibrosis score and FIB-4 index significantly decreased from baseline to weeks 12, 24 and 52 (Table 2). The type IV collagen 7S domain did not significantly change from baseline’’.

In the third paragraph of Discussion, the correct sentence is ‘‘Additionally, this study revealed improvement in the hepatic fibrosis biomarkers M2-BP, NAFLD fibrosis score, FIB-4 index, and ferritin following luseogliflozin administration in patients with T2DM complicated by hepatic dysfunction. However, type IV collagen 7S did not change significantly after luseogliflozin administration’’.

figure a
figure b

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hiroaki Seino.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Seino, H. Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial. Diabetes Ther 12, 2807–2811 (2021). https://doi.org/10.1007/s13300-021-01123-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13300-021-01123-w